Form 4: Galectin Therapeutics Director Eldred Kary Acquires Shares
SEC Form 4 Filing
Director Eldred Kary reports acquisition of Galectin Therapeutics shares at $0.82 per share, along with holdings in UTMA and trust accounts.
Summary
- On December 24, 2024, Eldred Kary, a director of Galectin Therapeutics Inc., acquired 13,469 shares of common stock at a price of $0.82 per share.
- Following the transaction, Kary directly owns 63,682 shares.
- Kary also indirectly owns 2,425 shares as UTMA custodian for a minor child and 2,000 shares held in trust.
- Kary disclaims beneficial ownership of the shares held as custodian and in trust.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director purchasing shares can be seen as a positive sign, but the filing itself is a routine disclosure.
Positives
- The director's purchase of shares could be interpreted as a positive signal about their confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's recent purchase of company stock.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 12/24/2024 | Date of transaction: Eldred Kary acquired shares of common stock. |
| 12/26/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.